Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ansan-si
Clinical trial register · South Korea

Clinical Trials in Ansan-si, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company10 Sanofi7 AbbVie6 Merck Sharp & Dohme LLC4 Incyte Corporation3
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Ansan-si

58 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Eli Lilly and Company
Phase 3
2,001
Ansan-si, Anyang-si, Busan, Guri-si, Gwangju, Junggu, Seogu, Seongnam
2026-08-26
Recruiting
Eli Lilly and Company
Phase 3
1,000
Ansan-si, Gwangju, Jeju City, Seoul
2026-08-14
Recruiting
Novo Nordisk A/S
Phase 2
270
Ansan-si, Yangsan, Seoul
2026-04-17
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
Wŏnju, Ansan-si, Seoul
2026-03-24
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Ansan-si, Seongnam-si, Incheon
2026-03-10
Recruiting
Eli Lilly and Company
Phase 3
800
Ansan-si, Seoul
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Ansan-si, Gwangju, Jeju City, Seoul
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,035
Ansan-si, Guri-si, Gwangju, Seongnam, Seoul
2025-12-15
Recruiting
Incyte Corporation
Phase 3
466
Ansan-si, Changwon-si, Daegu, Goyang-si, Seongnam-si, Seoul
2025-12-09
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Ansan-si, Cheonan, Gyeonggi-do, Incheon, Seoul
2025-11-24
Recruiting
Pfizer
Phase 2
200
Ansan-si, Busan, Seoul
2025-10-30
Recruiting
Eli Lilly and Company
Phase 3
4,500
Ansan-si, Bucheon-si, Busan, Daegu, Dongjak-gu, Guri-si, Incheon, Jinju
2025-10-15
Recruiting
Sanofi
Phase 3
980
Ansan-si, Busan, Daegu, Daejeon, Gwangju, Seoul, Suwon
2025-10-01
Recruiting
Neurocrine Biosciences
Phase 3
550
Ansan-si, Seoul
2025-08-18
Recruiting
Gilead Sciences
Phase 1/2
200
Ansan-si, Bucheon-si, Seoul
2025-07-31
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Ansan-si, Bucheon-si, Busan, Daejeon, Daejoen, Gwangju, Incheon, Seongnam
2025-07-22
Recruiting
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
NCT06962098Diabetic Kidney Disease (DKD)
Aptabio Therapeutics, Inc.
Phase 2
186
Ansan-si, Busan, Cheonan, Daegu, Goyang-si, Guri-si, Gwangmyeong, Incheon
2025-05-26
Recruiting
Hoffmann-La Roche
Phase 3
425
Ansan-si, Daegu, Gwangju, Seoul
2025-05-12
Recruiting
AstraZeneca
Phase 3
5,000
Ansan-si, Anyang-si, Busan, Cheonan-si, Goyang-si, Gwangju, Seongnam-si, Seoul
2025-03-03
Recruiting
Incyte Corporation
Phase 3
600
Ansan-si, Busan, Incheon, Seoul, Yangsan
2025-02-28
Active, closed
AbbVie
Phase 2
83
Ansan-si, Bucheon-si, Seoul
2024-12-19
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 3
1,714
Busan, Daegu, Gwangju, Ansan-si, Anyang-si, Bucheon-si, Hwaseong-si, Seongnam-si
2024-12-18
Recruiting
Pfizer
Phase 3
2,330
Namdong-gu, Tonggu, Wŏnju, Gwangju, Ansan-si, Suwon, Dongjak-gu, Gangnam-gu
2024-12-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Wŏnju, Gwangju, Ansan-si, Jinju, Pusan, Deagu, Seoul
2024-12-02
Active, closed
Incyte Corporation
Phase 3
349
Ansan-si, Bucheon-si, Busan, Incheon, Jeonju, Seoul
2024-10-10
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Ansan-si, Yongin-si, Seoul, Yeongdeungpo-gu, Gangwon-do
2024-09-26
Recruiting
AbbVie
Observational
3,000
Busan, Daejeon, Gangwon-do, Gwangju, Ansan-si, Goyang, Goyang-si, Hwaseong
2024-09-24
Active, closed
Boehringer Ingelheim
Phase 3
11,000
Ansan-si, Busan, Cheonan-si, Cheongju-si, Daegu, Deagu, Goyang-si, Guri-si
2024-08-30
Recruiting
AbbVie
Phase 3
675
Ansan-si, Bucheon-si, Seoul
2024-08-19
Active, closed
AbbVie
Phase 3
1,400
Busan, Cheonan-si, Ansan-si, Seongnam, Seoul
2024-06-27
Recruiting
AbbVie
Phase 3
200
Ansan-si, Bucheon-si, Suwon, Seoul
2024-06-14
Recruiting
LEO Pharma
Phase 3
195
Ansan-si, Gwangju, Seoul
2024-06-10
Recruiting
Cohort Study for Gastric MALT Lymphoma
NCT06454149Gastric MALT Lymphoma
Seoul National University Hospital
Observational
300
Ansan-si, Seongnam-si, Seoul
2024-06-06
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Wŏnju, Ansan-si, Suwon, Busan, Haeundae-gu, Dongjak-gu, Daegu, Daejeon
2024-06-05
Active, closed
Sanofi
Phase 3
1,541
Daegu, Gwangju, Ansan-si, Seongnam-si, Suwon, Yangsan, Bupyeong-gu, Seoul
2024-05-08
Active, closed
Eli Lilly and Company
Phase 3
301
Bupyeong-gu, Ansan-si, Seoul
2024-04-24
Active, closed
AstraZeneca
Phase 3
2,554
Ansan-si, Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Gwangju, Seoul
2024-03-29
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Ansan-si, Anyang-si, Bucheon-si, Gwangju, Seongnam, Seoul
2024-03-09
Active, closed
Sanofi
Phase 3
464
Ansan-si, Seongnam-si, Bupyeong-Gu, Seoul
2024-02-29
Active, closed
AstraZeneca
Phase 3
1,835
Ansan-si, Busan, Cheonan-si, Daegu, Goyang-si, Seoul
2023-11-07
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Ansan-si, Gwangju, Gyeonggi-do, Seoul
2023-10-12
Active, closed
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
NCT05846893Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Coronary Stenosis
B. Braun Medical Industries Sdn. Bhd.
Not applicable
1,436
Daegu, Chuncheon, Donggu, Ansan-si, Goyang-si, Changwon, Seoul
2023-09-07
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Buk-gu, Ansan-si, Seongnam-si, Yongin-si, Incheon, Seoul, Yeongdeungpo-gu, Gangwon-do
2023-07-11
Active, closed
AbbVie
Phase 3
1,328
Ansan-si, Seongnam, Seoul
2023-06-21
Active, closed
Eli Lilly and Company
Phase 3
3,127
Namdong-gu, Ansan-si, Anyang-si, Suwon, Busan, Seoul, Seogu
2023-06-05
Active, closed
Sanofi
Phase 2
999
Ansan-si, Bucheon-si, Yangsan, Incheon, Seoul
2023-04-03
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Wŏnju, Seongnam-si, Suwon, Daegu, Ansan-si, Busan, Daejeon, Incheon
2023-01-16
Recruiting
STabilization of Atheroma by Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB)
NCT05438121Coronary Artery Disease, Atherosclerotic Plaque, De Novo Stenosis
Korea University Ansan Hospital
Observational
65
Ansan-si
2022-10-13
Active, closed
Eli Lilly and Company
Phase 3
15,374
Ansan-si, Busan, Seongnam, Seoul, Wŏnju
2022-10-11
Active, closed
Biogen
Phase 2/3
450
Ansan-si, Suwon, Daejeon, Gwangju, Seoul
2022-09-13
Active, closed
Yonsei University
Observational
260
Busan, Chuncheon, Ansan-si, Goyang-si, Yongin-si, Daegu, Yangsan, Jeonju
2022-08-31
Active, closed
Sanofi
Phase 2/3
1,856
Daegu, Gwangju, Ansan-si, Seongnam-si, Suwon, Yangsan, Bupyeong-Gu, Seoul
2022-08-22
Recruiting
CHA University
Not applicable
240
Cheonan, Ansan-si, Goyang-si, Seongnam-si, Yangsan, Changwon, Hwasun, Busan
2022-08-01
Recruiting
Sanofi
Phase 3
284
Busan, Ansan-si, Seoul
2022-02-15
Active, closed
Eli Lilly and Company
Phase 3
996
Wŏnju, Ansan-si, Guri-si, Suwon, Gyeongsan-si, Busan, Haeundae-gu, Dongjak-gu
2020-06-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
6,033
Ansan-si, Seoul
2020-02-27
Active, closed
Sanofi
Observational
1,860
Ansan-si, Suwon, Incheon, Seoul
2019-08-15
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Ansan-si, Busan, Daegu, Gyeonggi-do, Hwaseong-si, Seongnam, Seongnam-si, Seoul
2018-04-13
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/ansan-si

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies with a site in Ansan-si.

How many clinical trials are recruiting in Ansan-si?

32 of the 58 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 26 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ansan-si), 58 studies
PhaseStudiesRecruitingShare
Phase 3402369%
Phase 27412.1%
Observational538.6%
Phase 2/3305.2%
Not applicable213.4%
Phase 1/2111.7%

Most active sponsors

Lead sponsors with the most studies (Ansan-si)
Lead sponsorStudiesRecruiting
Eli Lilly and Company106
Sanofi72
AbbVie63
Merck Sharp & Dohme LLC43
AstraZeneca31
Incyte Corporation32
Janssen Research & Development, LLC30
Boehringer Ingelheim21
Karuna Therapeutics, Inc., a Bristol Myers Squibb company22
Pfizer22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.